
San Diego biotech lands $120M to launch a slate of trials in neurosensory disorders
Days after adding some finance, dealmaking and technical talent to the top team, Escient Pharma has taken the wraps off a $120 million round to go broader in the clinic.
New Enterprise Associates, Abingworth and Forge Life Science Partners co-led the Series C. Escient did not return a request for comment.
The San Diego biotech has been turning a new page. At the beginning of the year, co-founder Alain Baron stepped down from the CEO post, making room for Joshua Grass — who brought on a trio of new execs earlier this month: Aaron Mishel, CFO; David Houck, VP of chemistry, manufacturing & controls; and Greg Balani, director of business development.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.